CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
October 31 2024 - 7:00AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
masked, conditionally activated biologic therapeutics, today
announced that it will report third quarter financial results on
Thursday, November 7, 2024, after the close of U.S. markets.
Following the announcement, the Company will host a conference call
and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
Participants may access the live webcast of the
conference call from the Events and Presentations page of CytomX’s
website at https://ir.cytomx.com/events-and-presentations. An
archived replay of the webcast will be available on the Company’s
website.
Audio Conference Call:
|
U.S. Dial-in
Number: |
|
(800)
715-9871 |
|
|
|
|
|
International Dial-in Number: |
|
(646) 307-1963 |
|
|
|
|
|
Conference ID: |
|
5171678 |
|
|
|
|
About CytomX Therapeutics,
Inc.CytomX is a clinical-stage, oncology-focused
biopharmaceutical company focused on developing novel conditionally
activated biologics designed to be localized to the tumor
microenvironment. By pioneering a novel pipeline of localized
biologics, powered by its PROBODY® therapeutic platform,
CytomX’s vision is to create safer, more effective therapies for
the treatment of cancer. CytomX’s robust and differentiated
pipeline comprises therapeutic candidates across multiple treatment
modalities including antibody-drug conjugates (“ADCs”), T-cell
engagers, and immune modulators such as cytokines. CytomX’s
clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904
is a conditionally activated T-cell-engaging bispecific antibody
targeting the epidermal growth factor receptor (EGFR) on tumor
cells and the CD3 receptor on T cells. CX-904 is partnered with
Amgen in a global co-development alliance. CX-2051 is a
conditionally activated ADC directed toward epithelial cell
adhesion molecule, EpCAM, with potential applicability across
multiple EpCAM-expressing epithelial cancers. CX-2051 was
discovered in collaboration with Immunogen, now part of AbbVie.
CX-801 is an interferon alpha-2b PROBODY® cytokine with broad
potential applicability in traditionally immuno-oncology sensitive
as well as insensitive (cold) tumors. CytomX has established
strategic collaborations with multiple leaders in oncology,
including Amgen, Astellas, Bristol Myers Squibb,
Regeneron and Moderna. For more information about CytomX and how it
is working to make conditionally activated treatments the new
standard-of-care in the fight against cancer,
visit www.cytomx.com and follow us
on LinkedIn and X (formerly
Twitter).
Company Contact:Chris
OgdenChief Financial Officercogden@cytomx.com
Investor Contact:Precision AQ
(formerly Stern Investor Relations)Stephanie
Ascherstephanie.ascher@precisionaq.com
Media Contact:Redhouse
CommunicationsTeri Dahlmanteri@redhousecomms.com
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Oct 2024 to Nov 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Nov 2023 to Nov 2024